Travere Therapeutics (TVTX) Short Interest Ratio & Short Volume $15.63 +0.18 (+1.17%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$15.23 -0.40 (-2.56%) As of 08/1/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Travere Therapeutics Short Interest DataTravere Therapeutics (TVTX) has a short interest of 12.86 million shares. This marks a 857,233.33% increase in short interest from the previous month. The short interest ratio (days to cover) is 7.9, indicating that it would take 7.9 days of the average trading volume of 1.19 million shares to cover all short positions.Current Short Interest12,860,000 sharesPrevious Short Interest1,500 sharesChange Vs. Previous Month+857,233.33%Dollar Volume Sold Short$210.65 millionShort Interest Ratio7.9 Days to CoverLast Record DateJuly 15, 2025Outstanding Shares88,810,000 sharesPercentage of Shares Shorted14.48%Today's Trading Volume764,859 sharesAverage Trading Volume1,190,838 sharesToday's Volume Vs. Average64% Short Selling Travere Therapeutics? Sign up to receive the latest short interest report for Travere Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartTVTX Short Interest Over TimeTVTX Days to Cover Over TimeTVTX Percentage of Float Shorted Over Time Travere Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/15/202512,860,000 shares $210.65 million +857,233.3%N/A7.9 $16.38 6/30/20251,500 shares $22.20 thousand -100.0%0.0%0 $14.80 6/15/202510,330,000 shares $149.79 million -17.4%12.1%5.9 $14.50 5/31/202512,500,000 shares $187.25 million +19.9%16.6%7.1 $14.98 5/15/202510,430,000 shares $220.59 million -2.0%13.9%5.8 $21.15 4/30/202510,640,000 shares $221.42 million -3.7%N/A5.7 $20.81 4/15/202511,050,000 shares $164.76 million -4.4%14.7%6.2 $14.91 3/31/202511,560,000 shares $207.16 million +3.3%15.4%6.6 $17.92 3/15/202511,190,000 shares $220.78 million +2.2%14.9%7 $19.73 2/28/202510,950,000 shares $234.33 million -3.1%14.6%7.2 $21.40 Get the Latest News and Ratings for TVTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/15/202511,300,000 shares $258.88 million +18.2%15.0%7.7 $22.91 1/31/20259,560,000 shares $195.60 million -0.2%N/A6.8 $20.46 1/15/20259,580,000 shares $173.11 million +9.9%N/A7.4 $18.07 12/31/20248,720,000 shares $151.90 million +17.7%N/A5.9 $17.42 12/15/20247,410,000 shares $128.34 million -2.1%N/A4.5 $17.32 11/30/20247,570,000 shares $142.39 million +8.6%N/A4.3 $18.81 11/15/20246,970,000 shares $123.51 million -12.8%N/A3.6 $17.72 10/31/20247,990,000 shares $139.83 million -1.5%N/A4.4 $17.50 10/15/20248,110,000 shares $143.47 million +16.5%N/A4.7 $17.69 9/30/20246,960,000 shares $97.37 million -19.6%N/A4.2 $13.99 9/15/20248,660,000 shares $116.74 million -6.4%N/A6.2 $13.48 8/31/20249,250,000 shares $87.60 million -0.5%N/A7.2 $9.47 8/15/20249,300,000 shares $81.65 million -7.8%N/A8.5 $8.78 7/31/202410,090,000 shares $96.26 million -0.1%N/A8.8 $9.54 7/15/202410,100,000 shares $99.08 million -2.1%N/A8.2 $9.81 6/30/202410,320,000 shares $84.83 million -23.1%N/A8.2 $8.22 6/15/202413,414,700 shares $96.18 million -0.4%N/A11 $7.17 5/31/202413,470,000 shares $99.95 million +0.2%N/A11.3 $7.42 5/15/202413,440,000 shares $91.39 million +4.9%N/A11 $6.80 4/30/202412,810,000 shares $70.84 million +8.6%N/A10.3 $5.53 4/15/202411,800,000 shares $74.58 million +11.3%N/A9.9 $6.32 3/31/202410,600,000 shares $81.73 million +5.3%N/A8.8 $7.71 3/15/202410,070,000 shares $75.42 million -1.9%N/A8.2 $7.49 2/29/202410,260,000 shares $77.57 million +5.1%N/A7.5 $7.56 2/15/20249,760,000 shares $85.30 million -1.7%N/A6.7 $8.74 1/31/20249,930,000 shares $88.67 million +2.3%N/A6.3 $8.93 1/15/20249,710,000 shares $92.54 million -2.1%N/A5.8 $9.53 12/31/20239,920,000 shares $89.18 million +2.9%N/A5.9 $8.99 12/15/20239,640,000 shares $83.48 million -3.1%N/A5.8 $8.66 11/30/20239,950,000 shares $62.49 million -6.7%N/A5 $6.28This Crypto Is Set to Explode in January (Ad)Billions Flowing Into Crypto (Here’s Where It’s Going!) Institutional money is flooding into crypto... Discover which coins they’re buying at the Crypto Hedge Fund Summit, before prices catch up.Claim your free seat now. 11/15/202310,660,000 shares $65.77 million +21.0%N/A5.9 $6.17 10/31/20238,810,000 shares $57.09 million +0.5%N/A5.2 $6.48 10/15/20238,770,000 shares $62.27 million +4.2%N/A5.6 $7.10 9/30/20238,420,000 shares $75.27 million -6.9%N/A5.8 $8.94 9/15/20239,040,000 shares $123.76 million +5.7%N/A6.7 $13.69 8/31/20238,550,000 shares $122.09 million +5.6%N/A8.3 $14.28 8/15/20238,100,000 shares $123.12 million +0.4%N/A7.6 $15.20 7/31/20238,070,000 shares $138.72 million -2.7%N/A7.3 $17.19 7/15/20238,290,000 shares $126.92 million -2.5%N/A6.5 $15.31 6/30/20238,500,000 shares $130.56 million +11.0%N/A6.3 $15.36 6/15/20237,660,000 shares $131.75 million +4.9%N/A5.4 $17.20 5/31/20237,300,000 shares $130.60 million -3.2%N/A5.4 $17.89 5/15/20237,540,000 shares $123.20 million -4.1%N/A4.7 $16.34 4/30/20237,860,000 shares $169.54 million -3.7%N/A4.7 $21.57 4/15/20238,160,000 shares $165.81 million -4.5%N/A5.6 $20.32 3/31/20238,540,000 shares $192.06 million +14.8%N/A5.7 $22.49 3/15/20237,440,000 shares $158.25 million -1.6%N/A5.4 $21.27 2/28/20237,560,000 shares $167.53 million +9.9%N/A5.7 $22.16 2/15/20236,880,000 shares $138.43 million -7.7%N/A5.8 $20.12 1/31/20237,450,000 shares $166.88 million -0.9%N/A8.8 $22.40 1/15/20237,520,000 shares $152.81 million -10.3%N/A9.1 $20.32 12/30/20228,380,000 shares $176.23 million +3.1%N/A10 $21.03 12/15/20228,130,000 shares $150.41 million -1.2%N/A9.7 $18.50 11/30/20228,230,000 shares $165.67 million +5.9%N/A10.6 $20.13 11/15/20227,770,000 shares $167.13 million -1.2%N/A10.4 $21.51 10/31/20227,860,000 shares $170.40 million +23.0%13.0%10.9 $21.68 10/15/20226,390,000 shares $132.15 million -6.2%10.6%8.4 $20.68 9/30/20226,810,000 shares $167.80 million +3.0%11.3%10.3 $24.64 9/15/20226,610,000 shares $179.79 million -0.5%11.0%9.9 $27.20 8/31/20226,640,000 shares $177.69 million -10.2%11.1%9 $26.76 8/15/20227,390,000 shares $211.28 million +7.9%12.3%9.7 $28.59 7/31/20226,850,000 shares $161.25 million +2.4%11.5%7.9 $23.54 7/15/20226,690,000 shares $163.97 million -5.0%11.2%8.4 $24.51 6/30/20227,040,000 shares $170.58 million +6.2%11.8%8.6 $24.23 6/15/20226,630,000 shares $160.18 million -10.4%11.1%8 $24.16 5/31/20227,400,000 shares $172.49 million -12.6%12.4%8.9 $23.31 5/15/20228,470,000 shares $187.86 million +3.7%14.2%9.7 $22.18 4/30/20228,170,000 shares $205.31 million +14.1%13.8%10.5 $25.13 4/15/20227,160,000 shares $212.22 million +0.7%12.1%9.3 $29.64 3/31/20227,110,000 shares $183.22 million -6.5%12.0%9.8 $25.77 3/15/20227,600,000 shares $181.72 million +29.3%12.8%11.5 $23.91 2/28/20225,880,000 shares $160.29 million -1.7%10.0%9.1 $27.26 2/15/20225,980,000 shares $171.39 million +11.4%10.5%11 $28.66 1/31/20225,370,000 shares $147.68 million +8.5%9.3%10.6 $27.50 1/15/20224,950,000 shares $136.32 million -15.5%8.5%9.3 $27.54 12/31/20215,860,000 shares $181.89 million -6.4%N/A0 $31.04 12/15/20216,260,000 shares $182.48 million +0.6%10.8%11.6 $29.15 11/30/20216,220,000 shares $177.58 million +3.0%10.7%10.5 $28.55 11/15/20216,040,000 shares $177.39 million -1.2%10.4%9.7 $29.37 10/29/20216,110,000 shares $176.03 million +0.5%10.1%5 $28.81This Crypto Is Set to Explode in January (Ad)Billions Flowing Into Crypto (Here’s Where It’s Going!) Institutional money is flooding into crypto... Discover which coins they’re buying at the Crypto Hedge Fund Summit, before prices catch up.Claim your free seat now. 10/15/20216,080,000 shares $148.96 million -6.9%10.2%5.1 $24.50 9/30/20216,530,000 shares $158.35 million -5.6%10.9%5.4 $24.25 9/15/20216,920,000 shares $162.83 million -3.1%11.5%5.4 $23.53 8/31/20217,140,000 shares $155.87 million +6.7%11.9%5.5 $21.83 8/13/20216,690,000 shares $103.36 million -1.6%11.2%4.9 $15.45 7/30/20216,800,000 shares $93.50 million +2.6%11.4%8.3 $13.75 7/15/20216,630,000 shares $90.83 million -1.5%11.1%8 $13.70 6/30/20216,730,000 shares $98.19 million +23.0%11.3%8.3 $14.59 6/15/20215,470,000 shares $81.67 million +19.4%9.2%7.5 $14.93 5/28/20214,580,000 shares $69.48 million -0.4%7.7%7 $15.17 5/14/20214,600,000 shares $86.94 million -3.2%7.7%8.7 $18.90 4/30/20214,750,000 shares $117.85 million -1.5%8.0%8.2 $24.81 4/15/20214,820,000 shares $122.48 million -6.4%8.1%7.7 $25.41 3/31/20215,150,000 shares $125.25 million +20.9%8.6%8.3 $24.32 3/15/20214,260,000 shares $122.43 million +3.2%7.2%6.9 $28.74 2/26/20214,130,000 shares $122.66 million -1.7%7.0%6.9 $29.70 2/12/20214,200,000 shares $116.72 million -0.7%7.4%7.3 $27.79 1/29/20214,230,000 shares $109.09 million -2.8%8.4%8.9 $25.79 1/15/20214,350,000 shares $126.67 million No Change8.6%11.1 $29.12 TVTX Short Interest - Frequently Asked Questions What is Travere Therapeutics' current short interest? Short interest is the volume of Travere Therapeutics shares that have been sold short but have not yet been covered or closed out. As of July 15th, investors have sold 12,860,000 shares of TVTX short. Learn More on Travere Therapeutics' current short interest. What is a good short interest ratio for Travere Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. TVTX shares currently have a short interest ratio of 8.0. Learn More on Travere Therapeutics's short interest ratio. Which institutional investors are shorting Travere Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Travere Therapeutics: Jane Street Group LLC, and Wolverine Asset Management LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Travere Therapeutics' short interest increasing or decreasing? Travere Therapeutics saw a increase in short interest in the month of July. As of July 15th, there was short interest totaling 12,860,000 shares, an increase of 857,233.3% from the previous total of 1,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Travere Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Travere Therapeutics: Lantheus Holdings, Inc. (12.25%), Axsome Therapeutics, Inc. (7.37%), Vaxcyte, Inc. (10.56%), Merus N.V. (6.56%), Cytokinetics, Incorporated (13.64%), Avidity Biosciences, Inc. (13.49%), ADMA Biologics Inc (6.06%), Krystal Biotech, Inc. (10.87%), Abivax SA Sponsored ADR (2.57%), Zai Lab Limited Unsponsored ADR (3.58%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Coinbase Global, Inc. ($5.11 billion), Charter Communications, Inc. ($4.76 billion), Reddit Inc. ($2.84 billion), SoFi Technologies, Inc. ($2.79 billion), Seagate Technology Holdings PLC ($2.79 billion), Live Nation Entertainment, Inc. ($2.67 billion), Rocket Lab Corporation ($2.49 billion), AST SpaceMobile, Inc. ($2.12 billion), Moderna, Inc. ($2.09 billion), and Omnicom Group Inc. ($2.04 billion). View all of the most shorted stocks. What does it mean to sell short Travere Therapeutics stock? Short selling TVTX is an investing strategy that aims to generate trading profit from Travere Therapeutics as its price is falling. TVTX shares are trading up $0.18 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Travere Therapeutics? A short squeeze for Travere Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of TVTX, which in turn drives the price of the stock up even further. How often is Travere Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TVTX, twice per month. The most recent reporting period available is July, 15 2025. More Short Interest Resources from MarketBeat Related Companies Lantheus Short Interest Data Axsome Therapeutics Short Interest Data Vaxcyte Short Interest Data Merus Short Interest Data Cytokinetics Short Interest Data Avidity Biosciences Short Interest Data ADMA Biologics Short Interest Data Krystal Biotech Short Interest Data Abivax Short Interest Data Zai Lab Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:TVTX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
